Patient compliance in the use of Vivotif Berna® Vaccine, typhoid vaccine, live oral Ty21a

Journal of Travel Medicine

Volumn 5, Issue 1, 1998, Pages 14-17

  Cryz Jr , Stanley J ^a  

^a Berna Biotech AG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLERA VACCINE; LIVE VACCINE; TYPHOID VACCINE;

ARTICLE; COUNSELING; DRUG STORAGE; HUMAN; MAJOR CLINICAL STUDY; NORTH AMERICA; ORAL DRUG ADMINISTRATION; PATIENT COMPLIANCE; QUESTIONNAIRE; TRAVEL;

ADMINISTRATION, ORAL; ADULT; DRUG STORAGE; HUMANS; PATIENT COMPLIANCE; PATIENT EDUCATION; POLYSACCHARIDES, BACTERIAL; QUESTIONNAIRES; TRAVEL; TYPHOID FEVER; TYPHOID-PARATYPHOID VACCINES; VACCINES, ATTENUATED;

EID: 0031940678     PISSN: 11951982     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1708-8305.1998.tb00449.x     Document Type: Article

References (15)

1. Levine MM, Ferreccio C, Black RE, Germanier R, Chilean Typhoid Committee. Large-scale field trial of Ty21a live oral typhoid vaccine in enteric-coated capsule formulation. Lancet 1987;(i):1049-1052.
2. Simanjuntak CH, Paleologo FP, Punjabi NH, et al. Oral immunisation against typhoid fever in Indonesia with Ty21a vaccine. Lancet 1991; 338:1055-1059.
3. Ferreccio C, Levine MM, Rodriquez H, Contreras R, Chilean Typhoid Committee. Comparative efficacy of two, three or four doses of Ty21a live oral typhoid vaccine in enteric-coated capsules. A field trial in an endemic area. J Infect Dis 1989; 159:766-769.
4. Levine MM, Kaper JB, Herrington D, et al. Safety, immunogenicity, and efficacy of recombinant live oral cholera vaccines, CVD 103 and CVD 103-HgR. Lancet 1988; August 27:467-470.
5. Wolfe MS. Precautions with oral live typhoid (Ty21a) vaccine. Lancet 1990; 336:631-632.
6. Marullo S, Jaccard A, Roulot D, et al. Inhibition of the Salmonella typhi oral vaccine strain, Ty21a, by mefloquine and chloroquine. J Infect Dis 1992; 166:1462-1464.
7. Kaplan DT, Hill DR. Compliance with live, oral Ty21a typhoid vaccine. JAMA 1992; 267:1074.
8. Rahman S, Barr W, Hilton E. Use of oral typhoid vaccine strain Ty21a in a New York State travel immunization facility. Am J Trop Med Hyg 1993;48:823.
9. Cryz SJ Jr. Post-marketing experience with live oral Ty21a vaccine. Lancet 1993; 341:49-50.
10. Kotloff KL, Wasserman SS, O'Donnell S, et al. Safety and immunogenicity in North Americans of a single dose of live oral cholera vaccine CVD 103-HgR: results of a randomized, placebo-controlled, double-blind crossover trial. Infect Immun 1992; 60:4430-4432.
11. Simanjuntak CH, O'Hanley P, Punjabi NH, et al. Safety, immunogenicity, and transmissibility of single-dose live oral cholera vaccine strain CVD 103-HgR in 24- to 59-month-old Indonesian children. J Infect Dis 1993; 168:1169-1176.
12. ™ vaccine. J Travel Med 1997; 4: 32-37.
13. Data on File. Swiss Serum and Vaccine Institute, Bern, Switzerland.
14. Kollaritsch H, Que JU, Kunz C, et al. Safety and immunogenicity of live oral cholera and typhoid vaccines administered alone or in combination with anti-malaria drugs, oral polio vaccine or yellow fever vaccine. J Infect Dis 1997; 175: 871-875.
15. Sbarbaro JA. The patient-physician relationship: compliance revisited. Ann Allergy 1990; 64:325-331.